Trial
NCT05209529
Chemo-free BRCA-targeted Neoadjuvant Strategy
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
European Organisation for Research and Treatment of Cancer - EORTC
Collaborators
AstraZeneca
Condition
TNBC - Triple-Negative Breast Cancer
Intervention
olaparib
Why stopped
Withdrawn interest from grant provider
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2024-02-23